Disease · MONDO_0005153

cervical adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cervical adenocarcinoma. Diseases, record MONDO_0005153. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005153

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cervical adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005153; Open Targets
Other names: adenocarcinoma - cervix, adenocarcinoma cervix uteri, adenocarcinoma of cervix, adenocarcinoma of cervix uteri, adenocarcinoma of the cervix, adenocarcinoma of the cervix uteri, adenocarcinoma of the uterine cervix, adenocarcinoma of uterine cervix, cervix adenocarcinoma, cervix uteri adenocarcinoma, uterine cervix adenocarcinoma; Open Targets
Disease Ontology: DOID:3702; Disease Ontology
NCI Thesaurus: C4029; NCI Thesaurus
Orphanet: ORPHA:213772; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SACITUZUMAB TIRUMOTECAN	CHEMBL5314875	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SERPLULIMAB	CHEMBL4594550	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 2	https://conductscience.org/library/genes/2618	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03257267	Study of Cemiplimab in Adults With Cervical Cancer	Phase 3	608	2022-04-06	Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT02868892	A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas	Phase 2	6	2018-11-02	Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix	PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT06419673	Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer	Phase 2	240		Cervical Cancer	CARBOPLATIN, CISPLATIN, SERPLULIMAB	Its record names the disease	ClinicalTrials.gov
NCT05492123	Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer	Phase 2	112		Uterine Cervical Neoplasms	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01097252	Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer	Phase 3	104		Cervical Cancers	CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT06752135	Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience		97		Cervical Carcinoma	CARBOPLATIN, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT07256236	SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer	Phase 2	89		Cervical Cancer	SACITUZUMAB TIRUMOTECAN	Its record names the disease	ClinicalTrials.gov
NCT05234905	H101 Combined With Camrelizumab for Recurrent Cervical Cancer	Phase 2	55		Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab	CAMRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06805864	Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma	Phase 2	45		Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Cemiplimab vs Investigator Choice (IC) Chemotherapy: Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1	52 of 304	19 of 304	608	NCT03257267

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21840137	RESULT	1	PubMed
41958171	DERIVED	1	PubMed
35922251	DERIVED	1	PubMed
35139273	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005153

GET https://conductscience.org/api/diseases/v1/MONDO_0005153/drugs

API reference For AI assistants